$26.850
+0.615 (+2.29%)收盘时
价格预测
在 App 中打开以解锁更长周期的预测。
Loading chart…
该买入 Apnimed Inc 股票吗？
Apnimed, Inc. is a good buy right now due to its strong recent performance, with a year-to-date change of +85.69% and a positive analyst outlook, including a target price of $60 from Cantor Fitzgerald. The upcoming FDA decision for its lead product, Oxnimbi, on February 28, 2027, adds a significant potential catalyst for growth. However, the main risk is the regulatory scrutiny associated with the FDA approval process, which could impact the stock negatively.
APMD 股价于 Tuesday 收于 $26.85，此前上涨 +2.29%
Apnimed Inc (APMD) last closed at $26.85, gaining +2.29%. These facts feed the 1-day and 1-week APMD price prediction above.
预测驱动因素
Apnimed Inc（APMD）的预测驱动因素综合了相似的图表形态、季节性与移动平均线。
Seasonality
Positive
Bullish
APMD 季节性分析
Loading chart…
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。